Wancong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wancong Zhang has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Shijie Tang
Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
13 shared publications - Yang Liu
Guangdong Provincial Key Laboratory of Marine Biotechnology, Department of Biology, College of Science, Shantou University, Shantou, Guangdong 515063, PR China
6 shared publications - Kit-Leong Cheong
College of Food Science and Technology, Guangdong Ocean University, Guangdong Provincial Key Laboratory of Aquatic Product Processing and Safety, Guangdong Province Engineering Laboratory for Marine Biological Products, Guangdong Provincial Engineering Technology Research Center of Seafood, Guangdong Provincial Engineering Technology Research Center of Prefabricated Seafood Processing and Quality Control, Zhanjiang 524088, China
5 shared publications Liyun Chen
Plastic Surgery Institute, Shantou University Medical College
3 shared publications- Liyun Chen
Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
3 shared publications - Bo Liu
Chemistry and Chemical Engineering Guangdong Laboratory, Shantou, China
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1944678
Case Report: Limb salvage in Vibrio vulnificus necrotizing fasciitis through sequential debridement and skin grafting
Background: Vibrio vulnificus ( V . vulnificus ) is a highly aggressive pathogen that causes rapidly progressing necrotizing fasciitis and septic shock, frequently leading to limb amputation or death. Limb salvage in this setting remains challenging, particularly in diabetic patients. Case presentation: A 72-year-old diabetic male developed V . vulnificus necrotizing fasciitis of the left upper limb after handling marine fish, presenting with local erythema, swelling, warmth, pain, and septic shock. He underwent five sequential debridement procedures combined with vacuum sealing drainage (VSD), followed by artificial dermis application and split-thickness skin grafting, ultimately achieving successful limb salvage. Conclusion: In this patient, serial reassessment, staged debridement with VSD, and delayed wound reconstruction were associated with infection control and limb preservation. This case may inform the multidisciplinary management of severe V. vulnificus necrotizing fasciitis.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1944678
Open AccessCase Report: Limb salvage in Vibrio vulnificus necrotizing fasciitis through sequential debridement and skin grafting
Background: Vibrio vulnificus ( V . vulnificus ) is a highly aggressive pathogen that causes rapidly progressing necrotizing fasciitis and septic shock, frequently leading to limb amputation or death. Limb salvage in this setting remains challenging, particularly in diabetic patients. Case presentation: A 72-year-old diabetic male developed V . vulnificus necrotizing fasciitis of the left upper limb after handling marine fish, presenting with local erythema, swelling, warmth, pain, and septic shock. He underwent five sequential debridement procedures combined with vacuum sealing drainage (VSD), followed by artificial dermis application and split-thickness skin grafting, ultimately achieving successful limb salvage. Conclusion: In this patient, serial reassessment, staged debridement with VSD, and delayed wound reconstruction were associated with infection control and limb preservation. This case may inform the multidisciplinary management of severe V. vulnificus necrotizing fasciitis.
- Open Access
- 30 September 2026
- Published by Springer Nature in Molecular Medicine
OncoCRISPRDB: an integrated platform for CRISPR screening data analysis in cancer research
- 30 September 2026
- Published by Springer Nature in Molecular Medicine
Open AccessOncoCRISPRDB: an integrated platform for CRISPR screening data analysis in cancer research
- Open Access
- 6 August 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Stem cell-assisted aligned electrospun nanofiber scaffold for tissue engineering: development to application
- 6 August 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessStem cell-assisted aligned electrospun nanofiber scaffold for tissue engineering: development to application
- Open Access
- 1 January 2026
- Published by Wiley in Stem Cells International
- Vol. 2026 (1) , 2759804
Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β‐cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP‐1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long‐term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β‐cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long‐term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance.
- 1 January 2026
- Published by Wiley in Stem Cells International
- Vol. 2026 (1) , 2759804
Open AccessMesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β‐cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP‐1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long‐term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β‐cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long‐term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance.
- Top Cited Papers
- 1 January 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 378, 961-981
Intelligent sequential degradation hydrogels by releasing bimetal-phenolic for enhanced diabetic wound healing
- 1 January 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 378, 961-981
Top Cited PapersIntelligent sequential degradation hydrogels by releasing bimetal-phenolic for enhanced diabetic wound healing
- Open Access
- 28 October 2024
- Published by Elsevier in Materials Today Bio
- Vol. 29, 101309
Recent advances in coaxial electrospun nanofibers for wound healing
- 28 October 2024
- Published by Elsevier in Materials Today Bio
- Vol. 29, 101309
Open AccessRecent advances in coaxial electrospun nanofibers for wound healing
- Open Access
Genome-wide Mendelian Randomization Identifies Potential Drug Targets for Dorsopathies
Background: Dorsopathies are a group of musculoskeletal disorders affecting the spinal column and related structures, contributing significantly to global disability rates and healthcare costs. Despite their prevalence, the genetic and biological mechanisms underlying dorsopathies are not fully understood. Method: Summary-data-based Mendelian Randomization (SMR) and colocalization analysis were employed, using data from genome-wide association studies (GWAS) and cis-expression quantitative trait loci (cis-eQTLs) databases. Genes with a colocalization posterior probability (PP.H4) above 0.7 in SMR results were selected for additional analysis. These selected genes underwent MR analysis to examine possible causal connections with dorsopathies, and sensitivity analyses were carried out to ensure robustness. Additionally, two transcriptome-wide association studies (TWAS) were utilized to confirm and screen for potential drug targets. Result: We identified four essential genes linked to dorsopathies: NLRC4 , CGREF1 , KHK , and RNF212 . Mendelian randomization (MR) analysis revealed a potential causal link between these genes and dorsopathies. Elevated transcription levels of NLRC4 , CGREF1 , and KHK correlated with reduced dorsopathies risk, while increased levels of RNF212 were associated with heightened risk of dorsopathies. Regarding methylation sites, an increase in cg04686953 fully mediated the decreased risk of dorsopathies by RNF212 . Similarly, the risk effect of cg26638505 and cg18948125 was entirely mediated by NLRC4 , while CGREF1 predominantly mediated the risk-increasing effect of cg06112415 and the decrease effect of cg22740783 . Conclusion: Dorsopathies were associated with four pivotal genes: NLRC4 , CGREF1 , KHK , and RNF212 . Methylation analysis identified cg04686953 and cg22740783 as protective against dorsopathies risk, while cg26638505 , cg18948125 , and cg06112415 exhibited a risk-increasing impact.
Open AccessGenome-wide Mendelian Randomization Identifies Potential Drug Targets for Dorsopathies
Background: Dorsopathies are a group of musculoskeletal disorders affecting the spinal column and related structures, contributing significantly to global disability rates and healthcare costs. Despite their prevalence, the genetic and biological mechanisms underlying dorsopathies are not fully understood. Method: Summary-data-based Mendelian Randomization (SMR) and colocalization analysis were employed, using data from genome-wide association studies (GWAS) and cis-expression quantitative trait loci (cis-eQTLs) databases. Genes with a colocalization posterior probability (PP.H4) above 0.7 in SMR results were selected for additional analysis. These selected genes underwent MR analysis to examine possible causal connections with dorsopathies, and sensitivity analyses were carried out to ensure robustness. Additionally, two transcriptome-wide association studies (TWAS) were utilized to confirm and screen for potential drug targets. Result: We identified four essential genes linked to dorsopathies: NLRC4 , CGREF1 , KHK , and RNF212 . Mendelian randomization (MR) analysis revealed a potential causal link between these genes and dorsopathies. Elevated transcription levels of NLRC4 , CGREF1 , and KHK correlated with reduced dorsopathies risk, while increased levels of RNF212 were associated with heightened risk of dorsopathies. Regarding methylation sites, an increase in cg04686953 fully mediated the decreased risk of dorsopathies by RNF212 . Similarly, the risk effect of cg26638505 and cg18948125 was entirely mediated by NLRC4 , while CGREF1 predominantly mediated the risk-increasing effect of cg06112415 and the decrease effect of cg22740783 . Conclusion: Dorsopathies were associated with four pivotal genes: NLRC4 , CGREF1 , KHK , and RNF212 . Methylation analysis identified cg04686953 and cg22740783 as protective against dorsopathies risk, while cg26638505 , cg18948125 , and cg06112415 exhibited a risk-increasing impact.
- Open Access
Identifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data
Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.
Open AccessIdentifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data
Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.
- 1 February 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 278, 118898
Effects of laminarin zwitterionic carboxylate and sulfonate on the intestinal barrier function and gut microbiota
- 1 February 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 278, 118898
Effects of laminarin zwitterionic carboxylate and sulfonate on the intestinal barrier function and gut microbiota
- 1 January 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 275, 118696
Bioactive polysaccharides from red seaweed as potent food supplements: a systematic review of their extraction, purification, and biological activities
- 1 January 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 275, 118696
Bioactive polysaccharides from red seaweed as potent food supplements: a systematic review of their extraction, purification, and biological activities